与塞马格卢提德和蒂尔泽帕提德相关的Allodynia和失声症
1Endocrinology, Diabetes and Metabolism, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Cureus
|November 10, 2025
概括
类似葡萄糖类-1 (GLP-1) 激动剂,如西马格卢提德和蒂尔泽帕提德,可以引起神经疼痛 (听觉障碍). 这种不良反应依赖于剂量,在停止药物治疗后会消失.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 神经学 神经学
背景情况:
- 赛马格卢提德和蒂尔泽帕提德是GLP-1和GLP-1/GIP受体的激动剂.
- 这些药物广泛用于2型糖尿病和体重管理.
- 与神经相关的副作用,如听力障碍,已被注意到与semaglutide.
研究的目的:
- 报告与蒂尔泽帕提德使用相关的失声症病例.
- 为了补充关于赛马格卢提德诱导的麻醉症的现有文献.
- 为了描述药物诱导的麻醉症的发生和解决.
主要方法:
- 病例报告详细介绍了药物不良反应.
- 审查患者报告的症状和病史.
- 在停止服用药物后观察症状的消失.
主要成果:
- 一位服用提尔泽帕提德的患者经历了失眠症.
- 同时还观察到与塞马格卢提德相关的听障症.
- 副作用似乎取决于剂量.
- 症状在停止服用药物后消失.
结论:
- 麻醉是塞马格卢提德和蒂尔泽帕提德的一种潜在不良反应.
- 这种副作用可能发生在治疗糖尿病和体重管理的患者中.
- 及时识别和停止药物可以导致症状的消失.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
863
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
863
Drugs for Treatment of Diarrhea-Predominant IBS
612
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
612
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
797
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
797
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
543
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
543
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
581
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
581
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K


